{"id":1068363,"date":"2022-12-08T00:13:57","date_gmt":"2022-12-08T05:13:57","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/qualigen-therapeutics-announces-pre-ind-feedback-from-u-s-food-and-drug-administration-regarding-qn-302-for-the-treatment-of-g4-targeted-advanced\/"},"modified":"2024-08-18T11:46:22","modified_gmt":"2024-08-18T15:46:22","slug":"qualigen-therapeutics-announces-pre-ind-feedback-from-u-s-food-and-drug-administration-regarding-qn-302-for-the-treatment-of-g4-targeted-advanced","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/qualigen-therapeutics-announces-pre-ind-feedback-from-u-s-food-and-drug-administration-regarding-qn-302-for-the-treatment-of-g4-targeted-advanced.php","title":{"rendered":"Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced&#8230;"},"content":{"rendered":"<p><![CDATA[CARLSBAD, Calif., Dec.  07, 2022  (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (\u201cQualigen\u201d or \u201cthe Company,\u201d Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received feedback from the FDA following a pre-Investigational New Drug (pre-IND) interaction regarding the development pathway to a Phase 1 clinical trial of QN-302 for the treatment of G4-targeted advanced solid tumors. The purpose of the pre-IND interaction was to inform the proposed content of the Company\u2019s IND application and request guidance from the Division on specific questions prior to submission of the IND application. The FDA\u2019s response provides Qualigen with clear guidance for formally submitting an IND application for QN-302 after accounting for the agency\u2019s comments and suggestions.]]><\/p>\n<p>Read the original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/07\/2569416\/0\/en\/Qualigen-Therapeutics-Announces-Pre-IND-Feedback-from-U-S-Food-and-Drug-Administration-Regarding-QN-302-for-the-Treatment-of-G4-Targeted-Advanced-Solid-Tumors.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced...\">Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original here: Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/qualigen-therapeutics-announces-pre-ind-feedback-from-u-s-food-and-drug-administration-regarding-qn-302-for-the-treatment-of-g4-targeted-advanced.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068363","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068363"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068363"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068363\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}